-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
First, the main point of view First, the global health care big data field has been active in the past 6 years, the establishment of early enterprises have a number of companies business model mature, and already have successfully listed companies;
, 2020, there were 111 financing incidents in the health care big data sector, with cumulative financing of more than $3.3 billion, an increase of 17% YoY, while the average financing amount of a single financing has been close to $30 million, basically the same as in 2019, and the development is more stable.
3. In the health care big data segment, the "AI plus big data" model of the company's relatively strong ability to attract gold, domestic, with a mature business model of this kind of companies to break through, not far from the listing, overseas, this type of start-up is also increasing, and there is a trend of further segmentation of the disease data field.
4, health care big data track in China has gradually entered the stage of development, the overall number of start-ups began to decline, the completion of the D-wheel and later rounds of financing enterprises are gradually increasing.
latest financing trends for health care big data in 2020: data granularity and disease tracks are gradually refining.